Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Catalent 1Q12 | Contract Pharma

What are you searching for?

Sign in
Breaking News

Financial Report: Catalent 1Q12

Oral Technologies revenue up 13%

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Catalent 1Q12

1Q Revenues: $410.5 million (+8%)

1Q Loss: $5.2 million (loss of $28.8 million 1Q11)

Comments: Oral Technologies revenue was $274.9 million (+13%), driven by continued demand for Rx softgel products and controlled release products. Sterile Technologies revenue was $52.7 million (-2%), due to lower flu and non-flu demand. Packaging Services revenue was $40.7 million (-12%), impacted by property and casualty loss at the company’s UK-based commercial packaging facility. Development & Clinical Services revenue was $47.6 million (+10%), attributed to a favorable product mix, expanded analytical services capabilities, and Clinical Services revenue (+13%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics